Skip to main content

Year: 2025

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 — cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced the first patient was dosed at The Ohio State University Wexner Medical Center for the Company-sponsored, multi-center first-in-human clinical trial...

Continue reading

Aeluma Joins the Midwest Microelectronics Consortium (MMEC) to Accelerate Pathway to Defense and Commercial Markets

Advancing U.S. Microelectronics Leadership Through Strategic Collaboration GOLETA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) — Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum computing, today announced that it has joined the Midwest Microelectronics Consortium (MMEC), a leading hub of microelectronics innovation and technology transition for the Department of Defense (DoD) Microelectronics Commons Program. “Aeluma was a founding affiliate member of the California DREAMS Hub, and now expands its industry presence with the MMEC Hub membership,” said Jonathan Klamkin, Ph.D., Founder and CEO of Aeluma. “Our scalable semiconductor photonics manufacturing platform addresses the needs in multiple key...

Continue reading

GXO’s State-of-the-Art Distribution Center in Germany Earns Aerospace Certification

EN 9120 aerospace certification elevates quality, traceability and compliance for distribution of commercial aircraft parts. DORMAGEN, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure‑play contract logistics provider, today announced that its multi‑user facility in Dormagen has been certified to EN 9120 (AS/EN 9120), the aerospace quality management standard for distributors. The certification elevates quality, traceability and compliance for commercial aircraft parts in Boeing’s dedicated area at GXO’s multi-user site in Dormagen, marking an important milestone in GXO’s multi‑year expansion in Germany and its commitment to high standards in Quality, Health, Safety, and Environment (QHSE) management. “GXO has long been an industry leader in providing mission-critical aerospace...

Continue reading

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference Company to Present and Host 1×1 Investor Meetings on Tuesday, December 2nd, 2025 AUSTIN, Texas, November 18, 2025 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Chief Executive Officer Ryan Rhodes is scheduled to present and, together with Chief Financial Officer Ken Mobeck, will host 1×1 investor meetings at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York City. Date:                     Tuesday, December 2nd Time:                  10:30-10:55 am ET (fireside discussion) Format:                Fireside discussion and 1×1 investor meetings Location:               The Lotte New York Palace  Webcast:              https://event.webcasts.com/starthere.jsp?ei=1743759&tp_key=aa01607b94...

Continue reading

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks another important milestone in our global strategy to expand access to bempedoic acid products for patients who urgently need better options to manage their LDL-C and reduce cardiovascular risk. We remain deeply committed to delivering innovative therapies that address unmet medical needs and improve outcomes for patients around the world,”...

Continue reading

REE Automotive and Mitsubishi Fuso Truck and Bus Corporation Sign MOU for Software-Defined Vehicle Technology

Mitsubishi Fuso is collaborating with REE as part of an acceleration strategy to shift into software-defined trucks that are smarter, safer, and upgradable over-the-air Mitsubishi Fuso is evaluating REE’s SDV and x-by-wire technologies for REE to serve as a potential supplier of a future vehicle platform The joint project has commenced and REE has begun integrating its SDV technology into a Mitsubishi Fuso eCanter electric truckTEL AVIV, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) — REE Automotive Ltd. (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today announced a strategic collaboration with Mitsubishi Fuso Truck and Bus Corporation (Mitsubishi Fuso) through a memorandum of understanding (MoU)1 to collaborate and develop a software-defined vehicle (SDV) using...

Continue reading

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolving tablet) drug delivery platform. The closing of the Melt acquisition marks a strategic expansion of Harrow’s portfolio and reinforces its commitment to delivering innovative therapies that improve patient outcomes. With global patent coverage and potential applications in ophthalmology, gastroenterology, dental...

Continue reading

Mesa Air Group Shareholders Approve Merger with Republic Airways

PHOENIX, Nov. 18, 2025 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (“Mesa” or the “Company”) (Nasdaq: MESA) announced today that shareholders approved all proposals presented at the Company’s special meeting of shareholders, including the proposal to adopt the agreement and plan of merger with Republic Airways Holdings Inc. (“Republic”) The merger proposal received 29,695,963 votes for, 185,635 votes against, and 37,271 abstentions, representing approximately 99.25% of votes cast. No broker non-votes were recorded. Shareholders representing approximately 71.4% of the outstanding shares entitled to vote were present in person or by proxy. “We appreciate the strong and clear support our shareholders have provided,” said Jonathan Ornstein, Mesa Chairman and CEO. “This vote confirms the strategic value of combining Mesa and Republic and...

Continue reading

Capital City Bank Rises in American Banker’s “Best Banks to Work For” List

Now No. 37 Nationwide and No. 8 Among Banks With $3–10 Billion in Assets TALLAHASSEE, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) — For the 13th consecutive year, Capital City Bank has been named one of American Banker’s “Best Banks to Work For.” In the 2025 rankings, the Bank placed #37 out of 90 banks nationwide and #8 in the category of banks with assets between $3 billion and $10 billion, a significant improvement over its 2024 rankings of #56 and #15, respectively. Capital City Bank has proudly served its communities for 130 years and is honored to continue this tradition of excellence. “This honor reflects the commitment of our associates, whose dedication and care define who we are as a company,” said Bill Smith, Capital City Bank Group chairman and CEO. “At Capital City Bank, we strive to foster a workplace culture where people...

Continue reading

Caliber Regains Compliance with Nasdaq Stockholders’ Equity Requirement

SCOTTSDALE, Ariz., Nov. 18, 2025 (GLOBE NEWSWIRE) — Caliber (Nasdaq: CWD), a diversified real estate and digital asset management platform, today announced that on November 17, 2025, it received notice from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders’ equity of at least $2,500,000, and that the matter is now considered closed. “We are pleased to have regained compliance with Nasdaq’s minimum stockholders’ equity requirement, reflecting our improved financial position and continued focus on building long-term shareholder value,” stated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.